No headlines found.
Globe Newswire (Tue, 16-Jun 8:33 AM ET)
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
Globe Newswire (Mon, 15-Jun 8:00 AM ET)
Globe Newswire (Tue, 12-May 8:00 AM ET)
OPKO Health Expands Nicoya Agreement to Support RAYALDEE Commercialization in Greater China
Globe Newswire (Thu, 30-Apr 8:30 AM ET)
Globe Newswire (Thu, 30-Apr 8:00 AM ET)
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Globe Newswire (Tue, 28-Apr 4:05 PM ET)
Globe Newswire (Wed, 22-Apr 8:00 AM ET)
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
Globe Newswire (Tue, 21-Apr 4:05 PM ET)
OPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
Globe Newswire (Wed, 8-Apr 8:00 AM ET)
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Opko Health trades on the NASDAQ stock market under the symbol OPK.
As of June 25, 2026, OPK stock price climbed to $1.50 with 975,865 million shares trading.
OPK has a beta of 1.30, meaning it tends to be more sensitive to market movements. OPK has a correlation of 0.17 to the broad based SPY ETF.
OPK has a market cap of $1.13 billion. This is considered a Small Cap stock.
Last quarter Opko Health reported $124 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-7 million and met earnings estimates .
In the last 3 years, OPK traded as high as $2.24 and as low as $.85.
The top ETF exchange traded funds that OPK belongs to (by Net Assets): IWM, VTI, VB, VXF, IWN.
OPK has underperformed the market in the last year with a return of +16.3%, while SPY returned +22.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OPK shares. However, OPK has outperformed the market in the last 3 month and 2 week periods, returning +32.7% and +4.2%, while SPY returned +12.6% and +1.4%, respectively. This indicates OPK has been having a stronger performance recently.
OPK support price is $1.44 and resistance is $1.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OPK shares will trade within this expected range on the day.